By Colin Kellaher

 

Shares of Leap Therapeutics Inc. rose more than 10% in premarket trading Wednesday after the biotechnology company reported positive data from a Phase 2a study of DKN-01, its most advanced clinical candidate, in combination with BeiGene Ltd.'s tislelizumab.

The Cambridge, Mass., company said the combination showed encouraging clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients.

Leap is conducting the study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia and New Zealand.

Leap shares, which closed Tuesday at $2.72, were recently up 11.4% to $3.03 in premarket trading.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

January 19, 2022 07:02 ET (12:02 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Leap Therapeutics Charts.
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Leap Therapeutics Charts.